|Voyager’s senior management team to highlight lead program VY-AADC for Parkinson’s disease, integration of novel capsid and delivery optimization efforts, and pipeline programs from the ALS, Huntington’s disease, Friedreich’s ataxia, anti-Tau antibody and severe chronic pain programs
CAMBRIDGE, Mass., Nov. 12, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, announced today it will host an R&D Day program and webcast for the investment community in New York City on November 16, 2017 from 2:00-5:00 p.m. EST. Members of Voyager Therapeutics’ senior management team, along with a guest movement disorder specialist speaker, will provide an overview of the following programs and initiatives:
- VY-AADC for advanced Parkinson’s disease
- Novel adeno-associated virus (AAV) capsids and delivery optimization efforts
- ALS, Huntington’s disease, Friedreich’s ataxia, anti-Tau antibody and severe chronic pain programs
Planned presenters include senior executives from Voyager Therapeutics’ scientific, clinical and management team, as well as a featured movement disorder specialist guest speaker:
- Steven Paul, M.D., president and chief executive officer
- Jane Henderson, chief financial officer and senior vice president of corporate development
- Bernard Ravina, M.D., M.S., chief medical officer
- Dinah Sah, Ph.D., chief scientific officer
- Matthew Ottmer, chief operating officer
- Luis Maranga, Ph.D., chief technical operations officer
- Andrew Siderowf, M.D., M.S., chief of the movement disorders division, University of Pennsylvania, Department of Neurology
Live-streaming webcast can be accessed through the Investors & Media sections of the Voyager’s website at www.voyagertherapeutics.com. The webcast will be archived for 30 days after the live event concludes.
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The company’s pipeline focuses on severe neurological diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of ALS, Huntington’s disease, Friedreich’s ataxia, frontotemporal dementia, Alzheimer’s disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com.
This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “undoubtedly,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward-looking statements. For example, all statements Voyager makes regarding the initiation, timing, progress and reporting of results of its preclinical programs and clinical trials and its research and development programs, its ability to advance its AAV-based gene therapies into, and successfully initiate, enroll and complete, clinical trials, the potential clinical utility of its product candidates, its ability to continue to develop its product engine, its ability to add new programs to its pipeline, its ability to enter into new partnerships or collaborations, its expected cash, cash equivalents and marketable debt securities at the end of a fiscal year and anticipation for how long expected cash, cash equivalents and marketable debt securities will last, and the timing or likelihood of its regulatory filings and approvals, are forward looking. All forward-looking statements are based on estimates and assumptions by Voyager’s management that, although Voyager believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected. Such risks and uncertainties include, among others, those related to the initiation and conduct of preclinical studies and clinical trials, the availability of data from clinical trials and the expectations for regulatory submissions and approvals; the continued development of the product engine; Voyager’s scientific approach and general development progress; the availability or commercial potential of Voyager’s product candidates; the sufficiency of cash resources; and need for additional financing. These statements are also subject to a number of material risks and uncertainties that are described in Voyager’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as updated by its subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Vice President of Investor Relations & Corporate Communications
Voyager Therapeutics, Inc.
Pure Communications, Inc.